Solving bacterial infections: How Phagos is using generative AI to change the way infectious diseases are treated

Phagos has a remarkable mission: to end bacterial disease. Today, Phagos is turning that vision into reality by harnessing bacteriophages, nature's bacteria-killing viruses, to cure infectious disease. Bacteriophages, or phages, are the natural regulators of bacteria. In an era of rising antibiotic resistance, there is an urgent need for this new antibacterial solution.

The key to phage therapy is finding the right phage for each target. Phages are the most abundant biological agent on the planet, making this a seemingly impossible task. That’s where AWS comes in.

“With Amazon SageMaker AI, we can create and run gen AI models that rapidly match phages to each target bacteria, which takes phage therapy from a manual trial-and-error process to precision medicine at scale,” says Adèle James, co-founder and CTO of Phagos.

AWS technologies allow Phagos to decode massive genomic datasets to develop these customized treatments in just two months, compared to the 10+ years that traditional antibiotic development requires.

Starting with animal farming applications, Phagos is already seeing results. After demonstrating efficacy over more than 10 clinical trials, it is now deploying its technology in France, where more than half a million animals have already been treated, with human applications on the horizon for 2030.

Learn more about how Phagos is turning vision into reality. Read the full case study.

Over 330,000 have joined AWS Activate since its inception in 2013, accessing a range of resources to help build, grow, and scale their startup. This includes unlocking AWS Activate Credits, which can be used to help cover the costs of AWS services and solutions, from compute, database, and storage; to machine learning, containers, applications, and more. AWS Activate has already provided more than $7 billion in credits to startups, and yours could be next to benefit. Find out more about AWS Activate today.